Ziopharm Oncology (ZIOP) to Present Updated Data for Gene Therapy Candidate Ad-RTS-hIL-12 + Veledimex in … – StreetInsider.com
|
Ziopharm Oncology (ZIOP) to Present Updated Data for Gene Therapy Candidate Ad-RTS-hIL-12 + Veledimex in …
StreetInsider.com Ad-RTS-hIL-12 + veledimex is a novel, viral gene therapy candidate for the controlled expression of interleukin-12 (IL-12), a pro-inflammatory cytokine critical for stimulating anti-cancer immune responses. Details for the poster presentation at ASCO … |
